Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8093 ↗At a glance
Journal article in Phytotherapy Research, 2024. Written by Zhao Fang and 6 co-authors. Institution: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China. Major MEDLINE topics: Heart Diseases, Cardiomyopathies, Sepsis, Flavonols. Cited 44 times so far (Crossref); 38 references. Funded by: Nature Science Foundation of China, Wuhan Knowledge Innovation Special Dawn Plan Project.
Topics: Sepsis
Abstract (original language)
Cardiac dysfunction and arrhythmia are severe complications of sepsis‐induced cardiomyopathy and are associated with an increased risk of morbidity and mortality. Currently, the precise mechanism for sepsis‐induced myocardial damage remains unclear. Astilbin, a flavonoid, is reported to have anti‐inflammatory, antioxidative, and antiapoptotic properties. However, the effects of astilbin on sepsis‐induced cardiomyopathy have not been studied so far. This study aims to investigate the effect of astilbin in sepsis‐induced myocardial injury and elucidate the underlying mechanism. In vivo and in vitro sepsis models were created using lipopolysaccharide (LPS) as an inducer in H9C2 cardiomyocytes and C57BL/6 mice, respectively. Our results demonstrated that astilbin reduced myocardial injury and improved cardiac function. Moreover, astilbin prolonged the QT and corrected QT intervals, attenuated myocardial electrical remodeling, and promoted gap junction protein (Cx43) and ion channels expression, thereby reducing the susceptibility of ventricular fibrillation. In addition, astilbin alleviated LPS‐induced inflammation, oxidative stress, and apoptosis. Astilbin suppressed the toll‐like receptor 4 (TLR4)/nuclear factor‐κB (NF‐κB) pathway in vivo and in vitro models. Astilbin remarkedly upregulated the nuclear factor erythroid 2‐related factor 2 (NRF2) and heme oxygenase 1 (HO‐1) expression. The in vitro treatment with an NRF2 inhibitor reversed the inhibition of the TLR4/NF‐κB pathway and antioxidant properties of astilbin. Astilbin attenuated LPS‐induced myocardial injury, cardiac dysfunction, susceptibility to VF, inflammation, oxidative stress, and apoptosis by activating the NRF2/HO‐1 pathway and inhibiting TLR4/ NF‐κB pathway. These results suggest that astilbin could be an effective and promising therapeutics target for the treatment of sepsis‐induced cardiomyopathy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
- Cardiovascular Research Institute, Wuhan University, Wuhan, China.
- Hubei Key Laboratory of Cardiology, Wuhan, China.
- Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
- Hubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
ORCID profiles: Chengyin Liu
Funding
- Nature Science Foundation of China
- Wuhan Knowledge Innovation Special Dawn Plan Project
Cite
APA
Fang, Z., Wang, G., Huang, R., Liu, C., Yushanjiang, F., Mao, T., & Li, J. (2024). Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway. Phytotherapy Research. https://doi.org/10.1002/ptr.8093
Vancouver
Fang Z, Wang G, Huang R, Liu C, Yushanjiang F, Mao T, et al. Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway. Phytotherapy Research. 2024. doi:10.1002/ptr.8093
BibTeX
@article{Fang2024,
author = {Fang, Zhao and Wang, Guangji and Huang, Rui and Liu, Chengyin and Yushanjiang, Feierkaiti and Mao, Tuohua and Li, Jun},
title = {Astilbin protects from sepsis‐induced cardiac injury through the NRF2 / HO ‐1 and TLR4 / NF‐κB pathway},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8093}
}
EUVIMED